Oritavancin matches vancomycin at treating skin infections
MRSA is among a group of infections for which a new single-dose antibiotic has been found as effective a treatment as vancomycin.
Oritavancin, now in a phase III trial, had similar efficacy as vancomycin at treating acute skin and skin-structure bacterial infections, including methicillin resistant Staphylococcus aureus (MRSA), the New England Journal of Medicine reported. Patients with a suspected gram positive skin infection received either a single intravenous 1,200mg dose of oritavancin (n=475) or seven to ten days of twice daily intravenous vancomycin (n=479). Oritavancin, a semi-synthetic lipoglycopeptide antibiotic, was as effective as vancomycin in all efficacy end points — such as reduction in lesion size and complete cure.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11138997
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com